Cytokinetics, Incorporated
NASDAQ: CYTK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert I. Blum
- Employees
- 673
- Headquarters
- South San Francisco, United States
- IPO year
- 2004
- Market cap
- $10.6B
- Website
- https://www.cytokinetics.com
Loading CYTK…
Loading profile data…Frequently asked questions about CYTK
What does Cytokinetics, Incorporated (CYTK) do?
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptom...
Where does CYTK trade?
Cytokinetics, Incorporated (CYTK) trades on the NASDAQ.
What sector is CYTK in?
Cytokinetics, Incorporated (CYTK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cytokinetics, Incorporated?
Robert I. Blum is the chief executive officer of Cytokinetics, Incorporated (CYTK).
Where is Cytokinetics, Incorporated headquartered?
Cytokinetics, Incorporated is headquartered in United States.
Does CYTK pay a dividend?
Cytokinetics, Incorporated (CYTK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYTK go public?
Cytokinetics, Incorporated (CYTK) completed its initial public offering in 2004.